Join to access to all OVN content. Join for Free

Results for 'Sue Watson'

...
Partner Avatar Michael Pietrack
Leadership Lab: 10 Ways Executives Can Stay Visible, Valuable Between Jobs

Oct 22nd • 5 mins read

...
Partner Avatar Michael Pietrack
Leadership Lab: How To Spot When Employees Are About To Walk Away

Oct 22nd • 7 mins read

...
Partner Avatar Michael Pietrack
Leadership Lab: 4 Ways Biopharma Leaders Can Prepare for Media Interviews

Aug 20th • 6 mins read

...
Partner Avatar Michael Pietrack
Managing Emotions After Being Downsized

Oct 21st • 5 mins read

...
Partner Avatar Michael Pietrack
How to Know When to Make a Job Change

Aug 26th • 5 mins read

...
Partner Avatar Michael Pietrack
The Four Employment Agreement Questions Every Pharma Executive Must Ask

Dec 18th • 6 mins read

...
Partner Avatar Tom Caravela
Interview Differentiator-Be a Story Teller

Mar 22nd • 1 min read

...
Partner Avatar Tom Caravela
Job Search Checklist for Aspiring Medical Science Liaisons

May 17th • 2 mins read

...
Partner Avatar Tom Caravela
MSL Retention – What Matters Most

Mar 15th • 2 mins read

...
Partner Avatar Tom Caravela
Promotability: How to Land Your Next Promotion

May 5th • 10 mins read

...
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Apr 7th • 12 mins read

...
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep
Accelerated drug approvals in oncology: Pros and cons

Sep 14th • 4 mins read

...
OVN Avatar Shani Paluch-Shimon, Nathan I. Cherny, Elisabeth G.E. de Vries, Urania Dafni, Martine J. Piccart, Nicola Jane Latino, Fatima Cardoso
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies

Sep 6th • 20 mins read

...
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Aug 16th • 8 mins read

...
OVN Avatar Audrey D. Zhang, Jeremy Puthumana, Nicholas S. Downing, MD
Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017

Apr 21st • 20 mins read

...
OVN Avatar Benjamin Gregory Carlisle, Adélaïde Doussau, Jonathan Kimmelman
Patient burden and clinical advances associated with post approval monotherapy cancer drug trials: a retrospective cohort study

Feb 17th • 7 mins read

...
OVN Avatar Carrie Printz
Precision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gaps

Jan 9th • 2 mins read

...
OVN Avatar Ruben Van Paemel, Roos Vlug, Katleen De Preter, Nadine Van Roy, Frank Speleman, Leen Willems, Tim Lammens, Geneviève Laureys, Gudrun Schleiermacher, Godelieve A. M. Tytgat, Kathy Astrahantseff, Hedwig Deubzer, Bram De Wilde
The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review

Jan 3rd • 10 mins read

...
OVN Avatar Jonathan H. Cheng, Justin W. Tiulim, Sheng Zhou, Anthony El-Khoueiry and Jorge Nieva
Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials

Oct 18th • 10 mins read

...
OVN Avatar Rinda Devi Bachu, Mariam Abou-Dahech, Swapnaa Balaji, Sai H. S. Boddu, Samson Amos, Vishal Singh, R. Jayachandra Babu, Amit K. Tiwari
Oncology biosimilars: New developments and future directions

Nov 25th • 30 mins read

Related Topics

Loading...